M/s Biological E. has established a state-of-the-art manufacturing facility to produce different vaccines. TDB has funded development & commercialization of the following vaccines.

Tetravalent – DTPw-r Hep-B
This vaccine after its development has undergone phase-III, human clinical trial and in this open, randomized non-inferiority study with tetravalent Diphtheria, Tetanus, Pertussis (whole cell) and recombinant Hepatitis B vaccine of Biological E. Limited was found to be safe and immunogenic in comparison with other control drugs in the market.

Monovalent – Heamophilus influenzae type b conjugate vaccine
Heamophilus type b Conjugate Vaccine (Tetanus Toxoid Conjugate), developed is produced both as a sterile liquid vaccine and as a sterile lyophilized vaccine. Both the types are meant for intramuscular use only. The vaccine consists of the Haemophilus b capsular polysaccharide (polyribosyl-ribitol-phosphate, PRP), a high molecular weight polymer.